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Abstract
The ability to mount an interferon response on sensing viral infection is a critical component of mammalian innate
immunity. Several viruses directly antagonize viral sensing pathways to block activation of the host immune response. Here,
we show that recurrent viral antagonism has shaped the evolution of the host protein MAVS—a crucial component of the
viral-sensing pathway in primates. From sequencing and phylogenetic analyses of MAVS from 21 simian primates, we found
that MAVS has evolved under strong positive selection. We focused on how this positive selection has shaped MAVS’
susceptibility to Hepatitis C virus (HCV). We functionally tested MAVS proteins from diverse primate species for their ability
to resist antagonism by HCV, which uses its protease NS3/4A to cleave human MAVS. We found that MAVS from multiple
primates are resistant to inhibition by the HCV protease. This resistance maps to single changes within the protease
cleavage site in MAVS, which protect MAVS from getting cleaved by the HCV protease. Remarkably, most of these changes
have been independently acquired at a single residue 506 that evolved under positive selection. We show that ‘‘escape’’
mutations lower affinity of the NS3 protease for MAVS and allow it to better restrict HCV replication. We further show that
NS3 proteases from all other primate hepaciviruses, including the highly divergent GBV-A and GBV-C viruses, are
functionally similar to HCV. We conclude that convergent evolution at residue 506 in multiple primates has resulted in
escape from antagonism by hepaciviruses. Our study provides a model whereby insights into the ancient history of viral
infections in primates can be gained using extant host and virus genes. Our analyses also provide a means by which
primates might clear infections by extant hepaciviruses like HCV.
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Introduction
Among the myriad of antiviral mechanisms employed by
mammalian cells, the ability to sense viral RNA has emerged as a
criticalcomponentofinnateimmunity.ViralRNAisdetectedinthe
cytoplasm by sensor proteins RIG-I and MDA-5 [1–3]. Both these
sensors act through a common downstream effector Mitochondrial
antiviral signaling (MAVS) (also known as IPS-1, VISA, and
Cardif), which in turn mounts an interferon response (schematic of
MAVS pathway in Figure S1) [4–7]. Given the importance of the
RNA virus-sensing pathway in the antiviral response, it is not
surprising that several highly diverse classes of viruses have evolved
ways to inhibit multiple steps of the viral-sensing pathway.
In particular, several viruses encode antagonists of MAVS
function [5,8–13]. Hepatitis C virus (HCV) encodes a protease
NS3, which in concert with its cofactor NS4A cleaves human
MAVS [5,8]. HCV is a single-stranded positive sense RNA virus
that belongs to the Flaviviridae class of viruses that causes chronic
liver disease and is estimated to infect 170 million people globally
(about 3% of the world’s population) [14,15]. HCV is known to
naturally infect only humans, although chimpanzees can also be
experimentally infected with it. GB viruses GBV-A, GBV-B, and
GBV-C are other HCV-related viruses belonging to the Flaviviridae
class that infect primates, although it is not clear whether they are
pathogenic to their hosts. We refer to all GB viruses as
hepaciviruses in this article, although some GB viruses have also
previously been referred to as Pegiviruses (the International
Committee on Taxonomy of Viruses has not yet formally assigned
GB viruses to any genus) [15]. Recently, HCV-like viruses have
also been found in non-primate mammalian species, specifically in
bats and dogs [16,17].
We investigated the functional consequences of MAVS
evolution, putatively driven by antagonism from ancient viruses
(paleoviruses). Viral antagonism can impose persistent selective
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selection (i.e., accumulation of an excess of nonsynonymous
changes relative to synonymous changes over evolutionary time).
Positive selection has been seen previously in many antiviral
factors characterized in primate genomes [18–24]. Positive
selection largely reflects adaptations to past viral infections, with
adaptive changes providing beneficial consequences for the host to
overcome viral antagonism. However, the resulting adaptive
changes can also influence resistance or susceptibility to present-
day viruses. For example, adaptive changes at key residues in the
antiviral gene Protein Kinase R (PKR), likely driven by ancient
viruses, are important determinants of PKR’s ability to resist
antagonism by present-day poxviruses [18,25]. Thus, antiviral
genes evolving under positive selection are good candidates to be
genetic determinants of resistance or susceptibility to present-day
viruses.
Here, we sought to determine whether MAVS has adaptively
evolved during primate history and whether this positive selection
has consequences for its resistance against HCV antagonism. We
found that MAVS has evolved under strong positive selection in
primates. We further found that one consequence of this selection
is that MAVS from multiple primate species has independently
become resistant to HCV antagonism. Remarkably, most of these
primate MAVS variants are resistant due to changes at the same
residue, and we dissect the functional consequences of this change
using a combination of biochemistry and virology. Finally, based
on functional analysis of other extant HCV-like viruses, we infer
that these adaptive ‘‘escape’’ changes in MAVS were likely driven
by ancient hepaciviruses, potentially providing paleoviral insights
into hepaciviral infections over the course of primate evolution.
Results
We sequenced and analyzed MAVS cDNA from a total of 21
simian primate species representing nearly 40 million years of
simian primate evolution (Figure 1A) [26]. The phylogeny
constructed with MAVS sequences was in agreement with the
recently published well-supported phylogeny of primates [26]. We
found that many residues in MAVS were highly conserved
throughout the course of 35 million years of primate evolution,
reflecting the constraint to maintain MAVS function via purifying
selection. However, using maximum-likelihood analyses [27,28],
we found that MAVS has evolved under strong positive selection
in primates. Specifically, models that allow the rate of nonsynon-
ymous (dN) changes to be greater than that for synonymous (dS)
changes are statistically a much better fit to the data than models
that disallow positive selection (p,0.001, Table 1). Although there
appears to be considerable variation in dN/dS ratios across
numerous branches of the MAVS phylogeny (Figure 1A),
according to branch-site random effects likelihood (REL) analysis,
no single branch has statistically significant evidence of positive
Author Summary
Hepatitis C virus (HCV) causes chronic liver disease and is
estimated to infect 170 million people worldwide. HCV is
able to establish a persistent infection in part by inhibiting
the innate immune response. It does so by using its
protease, NS3, to cleave the host’s antiviral factor MAVS,
which normally activates the interferon response. Using an
assay that measures MAVS activity, we found that multiple
primate species contain a version of MAVS that is resistant
to HCV antagonism. Surprisingly, most of these primates
have independently converged on changes in the same
amino acid residue of MAVS to escape cleavage by the
HCV protease. We found that the HCV protease has lower
binding affinity for these resistant MAVS variants, which
consequently are more effective at restricting HCV
infection. Using a combination of phylogenetic and
functional analyses of proteases from other HCV-related
viruses, we infer that ancestral primates were likely
exposed to and adapted to HCV-like viruses. One
consequence of this adaptation is that changes that have
given rise to extant MAVS variants may now provide
protection from modern-day viruses.
Figure 1. MAVS has evolved under positive selection in
primates. (A) dN/dS ratios for the MAVS gene, calculated using free-
ratio model in PAML, are shown on a phylogeny [26] along with
common and scientific names of the primate species represented.
Branches with dN/dS ratios greater than 1 are highlighted in red. For
branches that did not experience any synonymous (S) changes, number
of nonsynonymous (N) and S changes are shown in parentheses. (B)
Residues identified as being under recurrent positive selection are
indicated on a schematic of the MAVS protein, including the CARD,
Proline-rich, and transmembrane (TM) domains. CodeML program of
PAML software was used to identify sites under positive selection by
comparing M7 (beta) versus M8 (beta & v) models, assuming codon
frequencies according to the F61 model. Web-based implementation of
HyPhy package was used to perform REL analysis. We present only
those sites identified with a posterior probability higher than 0.9 in both
Bayes empirical Bayes (BEB) and random effects likelihood (REL)
methods.
doi:10.1371/journal.pbio.1001282.g001
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variable along branches do not have a statistically higher
likelihood than models that account for one common dN/dS
ratio across the entire phylogeny (p.0.05, Table 1) [27,28],
suggesting that positive selection is not confined to a few primate
lineages but is rather pervasive throughout the primate phylogeny.
In addition to inferences about adaptive evolution across the entire
MAVS protein, we can infer positive selection at the single amino
acid resolution based on recurrent nonsynonymous mutations at a
single position across multiple lineages (dN/dS.1 at a single
residue). According to maximum likelihood analysis using PAML
[27,28], 10 residues have high posterior probabilities of having
dN/dS greater than 1 (.0.9). Nine of these 10 residues are also
supported by an independent random effects likelihood (REL)
analysis (Figure 1B, Table S1) [30]. These findings of positive
selection are consistent with the hypothesis that MAVS has
encountered and adapted to viral antagonists throughout primate
history.
Given the rapid divergence of primate MAVS via positive
selection, we investigated whether MAVS alleles from different
primate species harbored functional variation in terms of their
susceptibility to antagonism by extant viruses. For instance, if
primates have encountered and adapted to escape antagonists
similar to HCV protease, then MAVS from some of these primate
species might be resistant to inhibition by HCV NS3/4A. We
tested this possibility using a facile assay to measure HCV NS3/4A
inhibition of MAVS activity. Over-expression of human MAVS in
cultured cells is sufficient to activate the interferon response, which
can be assayed by the IFN-b promoter-driven firefly luciferase
reporter. We cloned MAVS from 20 different primate species into
expression vectors with a strong CMV promoter and transiently
transfected them into human-derived 293T cells. We found that
MAVS from all primate species was capable of inducing IFN-b-
driven luciferase expression, despite relying on the signaling
machinery of human cells (Figure 2A, Figure S2). Consistent with
previous observations [5,8], we observed that co-expression of
HCV NS3/4A protease robustly inhibited human MAVS
signaling to the IFN-b promoter (Figure 2A). This inhibition is
specific to the HCV protease-mediated proteolysis at residue 508,
since introducing a C508R mutation in human MAVS blocks this
inhibition, as shown previously (Figure 2A) [8]. We found that
HCV NS3/4A also inhibited signaling driven by MAVS from
most primates. However, MAVS proteins from four species—olive
baboon, rhesus macaque, spider monkey, and dusky titi monkey—
were capable of significant IFN-b induction even in the presence
of the HCV protease (Figure 2A). Except for olive baboon and
rhesus macaque, all the ‘‘resistant’’ species are phylogenetically
well separated from each other by ‘‘susceptible’’ species
(Figure 1A). Thus, resistance to inhibition by HCV protease
appears to have been independently acquired at least three
different times.
We next investigated the molecular basis of MAVS resistance to
HCV NS3/4A inhibition. We found that MAVS from olive
baboon has the same cysteine to arginine change at position 508 as
in our positive control MAVS with C508R mutation (Figure 2B),
disrupting the protease cleavage site and thus providing an
explanation for its escape from HCV protease inhibition.
However, the cysteine at 508 is conserved in other ‘‘resistant’’
MAVS’ (Figure 2B), suggesting that genetic changes at different
residue(s) must be responsible for their resistance to HCV
protease. By examining the MAVS protein sequences from rhesus
macaque, spider monkey, and dusky titi monkey, we found that
changes at only a single residue, 506, can parsimoniously explain
MAVS escape from HCV protease antagonism in these variants
(Figure 2B). While most primate MAVS proteins have an ancestral
valine residue at position 506, the three HCV protease ‘‘resistant’’
MAVS’ have all independently altered this residue to either
glycine or alanine. We therefore considered the remarkable
possibility that MAVS has converged on the same escape strategy
multiple times in primate evolution. Consistent with escape from
viral antagonism being responsible for this convergent evolution,
residue 506 is one of nine MAVS residues with high statistical
support of having evolved under positive selection (Figure 1B,
Table 1).
To assess whether changes at position 506 are causal for
resistance to HCV NS3/4A protease, we swapped the evolved
glycine and alanine residues in rhesus macaque and spider monkey
MAVS, respectively, back to the ancestral valine (G506V and
A506V, Figure 3A). We found that both of these swapped MAVS
variants were capable of IFN-b induction and were now
susceptible to HCV NS3/4A inhibition (Figure 3A). Conversely,
changing the ancestral valine in human and talapoin MAVS to
glycine (V506G) and to alanine (V506A) in tamarin monkey
MAVS confers significant resistance to NS3/4A protease antag-
onism (Figure 3A). Taken together, these data demonstrate that
changes at residue 506 in MAVS are necessary and sufficient to
explain most of the variation in resistance and susceptibility
to the HCV NS3/4A protease among primate MAVS proteins.
However, not all changes appear to be equally protective. For
instance, Allen Swamp Monkey has a methionine instead of the
Table 1. Pervasive adaptive evolution of MAVS in primates.
Selection Models Codon Frequency Model Degrees of Freedom 22 X lnL l p Value
% Sites with dN/dS.1
(Average dN/dS)
M7 (beta) versus M8 (beta & v) F61 2 42.5 p,0.0001 7.7 (4.4)
F3X4 2 39.9 p,0.0001 7.8 (4.5)
M8a (beta & vs) versus M8 (beta & v) F61 1 41.3 p,0.0001 7.7 (4.4)
F3X4 1 39.3 p,0.0001 7.8 (4.5)
M0 (fixed v) versus M1 (variable v) F61 38 26.2 0.93 N/A
F3X4 38 30.7 0.80 N/A
M7 is a null model in which dN/dS (v).1 is not allowed. M7 assumes 0,v,1 is beta-distributed among sites, while M8a assumes 0, v#1. These null models are
compared to selection model M8 with an extra category that allows sites with v.1 in likelihood ratio tests. These comparisons support evolution of MAVS under
positive selection in primates. Models M0 and M1 are free-ratio models that are compared to test for branch-specific positive selection. M0 model allows all branches to
have the same common v, while M1 allows each branch to have its own v. This comparison does not support episodic selection of MAVS in primates. All analyses were
done using codeml program in PAML software.
doi:10.1371/journal.pbio.1001282.t001
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in the luciferase assay (Figure 2B, Figure 3A) (but see below).
Residue 506 occupies the P3 position of the NS3/4A protease
cleavage site, only two residues away from where the protease
cleaves MAVS (Figure 2). Previous studies have demonstrated
that this position is an important determinant of HCV
polyprotein cleavage by NS3/4A protease, with valine being
the preferred residue at P3 [31,32]. However, functional effects of
variation at the P3 position for MAVS cleavage were previously
unknown. We investigated whether ‘‘resistant’’ changes at residue
506 protect MAVS from cleavage by the viral protease
(Figure 3B). We found that ‘‘resistant’’ rhesus macaque and
spider monkey MAVS’ are not cleaved by the NS3/4A protease
(Figure 3B). However, single amino acid substitutions back to
ancestral valine render both rhesus macaque (G506V) and spider
monkey (A506V) MAVS’ susceptible to cleavage. Conversely,
V506G changes in human and talapoin MAVS and a V506A
change in tamarin monkey MAVS render these previously
susceptible variants to now become resistant to NS3/4A protease
cleavage (Figure 3B). Intriguingly, we also found that Allen’s
swamp monkey MAVS, which possesses a methionine at position
506, becomes more susceptible to cleavage when the methionine
is changed back to the ancestral valine (M506V) (Figure 2B,
Figure 3B), suggesting that methionine at 506 does offer
protection even though this was less evident from the IFN-b
induction assay (Figure 2A, Figure 3A). Thus, cleavage
susceptibility to HCV NS3/4A protease explains the variation
we saw in the IFN-b induction assay (Figure 2A, Figure 3A).
Figure 2. MAVS from multiple primate species is resistant to antagonism by HCV protease NS3/4A. (A) Induction of IFN-b promoter, as
measured by luciferase firefly activity, upon expression of MAVS cDNA from corresponding species coexpressed with (+) or without (2) HCV NS3/4A.
Primates with MAVS capable of significant IFN-b induction even in the presence of HCV protease are highlighted in bold. Human (C508R) refers to
substitution of Cysteine (C) at position 508 with Arginine (R) in human MAVS. Firefly luciferase activity is normalized as being 100% for MAVS from
each species in absence of HCV NS3/4A. All experiments are done in triplicates, and error bars indicate standard deviation. (B) Amino acid sequence of
MAVS (residues 503–514) from corresponding primates in (A). The scissor icon indicates HCV NS3/4A cleavage site. The P positions for the HCV
protease are indicated at the bottom of the alignment. Arginine (R) at residue 508 in olive baboon, believed to prevent MAVS cleavage, is boxed and
the C508R change in human MAVS is underlined. Position 506, highlighted in bold, correlates with the ability of primate MAVS to induce IFN-b even
in the presence of HCV NS3/4A protease as seen in (A). Changes away from the ancestral valine (V) at position 506 are indicated in red.
doi:10.1371/journal.pbio.1001282.g002
Evolution of Escape of MAVS from Hepaciviruses
PLoS Biology | www.plosbiology.org 4 March 2012 | Volume 10 | Issue 3 | e1001282To investigate the mechanism underlying cleavage resistance, we
testedthe importanceofresidue 506(positionP3) forstable complex
formation between NS3/4A and MAVS. To measure stable
interaction between NS3/4A and MAVS, we used the catalytically
inactive protease to prevent cleavage and release of MAVS from a
MAVS/NS3/4A complex. As the protease catalytic activity is
needed to cleave the protease polypeptide into NS3 and its cofactor
4A, which is required for proper NS3 function, we used a single
chain protease construct of NS3 that contains an active site
mutation to prevent MAVS cleavage, but contains the amino acids
of NS4A required for maximal protease activity fused to the amino
terminus of the NS3 protease (sc-NS3 (S1165A)) [33]. We observed
reduced binding of the HCV protease to human MAVS when the
‘‘susceptible’’ valine at residue 506 is mutated to ‘‘resistant’’ glycine
(Figure 3C). These data suggest that reduced binding between
MAVS and the protease contributes to protection from cleavage of
MAVS variants with ‘‘resistant’’ changes at position 506.
Next, we tested whether resistance to cleavage by the HCV
protease allows MAVS to restrict HCV replication with greater
efficiency during an infection. Cell lines that harbor subgenomic
HCV replicons provide a good model system to study HCV
replication [34]. Importantly, replication of this HCV genome is
susceptible to IFN-induced host responses [35]. We therefore used
a Huh7 cell line that harbors a HCV type 1b–derived replicon to
test whether cleavage-resistant variants of MAVS are better able to
restrict HCV replication [34]. Transient transfection of wildtype
human MAVS confers a nearly 2-fold higher protection against
HCV replication in cells (Figure 4). Moreover, transfection with
cleavage-resistant human MAVS (V506G) or rhesus MAVS
confers an additional 2-fold higher restriction of HCV replication,
which is equivalent to that achieved by complete loss of MAVS
cleavage due to mutation at the P1 position (C508Y) (Figure 4).
The actual level of resistance is likely underestimated in these
experiments since not all cells exposed to HCV replication were
expressing MAVS, which was transiently transfected. We conclude
from these experiments that resistant variants of MAVS are better
able to restrict HCV replication, with changes at residue 506 (P3
position) allowing MAVS to achieve the same level of HCV
restriction as the non-cleavable MAVS with mutation at the P1
position.
Statistical support of positive selection based on convergent
evolution in four independent lineages suggests that changes at
residue 506 represent adaptations driven by viral antagonists.
Functional analysis demonstrates that changes at this residue now
protect MAVS against cleavage by protease from an extant virus
HCV, allowing MAVS to better inhibit HCV replication. Taken
together, these data are consistent with the hypothesis that changes
at residue 506 represent adaptations to antagonism by proteases
from HCV-like viruses. To support this hypothesis, we wished to
test proteases from viruses that infect non-human primates that
might antagonize MAVS at the same position as the HCV
protease. The GBV-B virus is closely related to HCV and has been
Figure 3. Changes at residue 506 in MAVS protect it from cleavage by HCV NS3/4A protease. (A) Normalized induction of IFN-b promoter
by MAVS variants with the indicated changes, as measured by luciferase firefly activity, is presented in the presence or absence of HCV NS3/4A
protease. Evolutionary changes in amino acid at position 506 are highlighted in red. Firefly activity is normalized to be 100% in absence of HCV NS3/
4A. Experiments are done in triplicates, and error bars indicate standard deviation. (B) Immunoblot analysis showing MAVS, NS3/4A, and actin protein
from cells expressing the MAVS variant with or without NS3/4A according to corresponding labeling in (A). The human V506G MAVS variant was
expressed at low levels and is therefore shown at higher exposure (marked by dotted lines). Lowest size bands are non-specific in these samples. (C)
Co-immunoprecipitation analysis of MAVS with the single-chain (SC) HCV NS3/4A protease containing the protease active site mutation S1165A.
Extracts from HEK 293 cells expressing Flag-tagged human MAVS with either valine or glycine (in red) at position 506 and Myc-SC-NS3 (S1165A) were
immunoprecipitated using Flag-conjugated beads followed by immunoblot analysis.
doi:10.1371/journal.pbio.1001282.g003
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natural host is unknown, it has been shown to infect tamarins and
marmosets [36,37]. More distantly related to HCV are the GBV-
A and GBV-C (also known as hepatitis G) viruses, which are
known to naturally infect primates. GBV-A infects New World
monkeys while GBV-C is found in humans and chimps. These two
viruses have tentatively been assigned to a new Pegivirus genus, as
a sister genus to the Hepacivirus genus within the Flaviviridae
family (although this designation has not yet been formally
accepted by the International Committee on Taxonomy of
Viruses) [37–42]. We refer to the Hepacivirus/Pegivirus genera
as hepaciviruses here, for convenience and because of their shared
properties we observed (Figure 5). All GB viruses encode the NS3
protease. We therefore tested the ability of NS3 proteases from
these viruses to antagonize human MAVS. Consistent with our
hypothesis, we found that the NS3 protease from both GBV-A and
GBV-C strongly inhibited signaling by human MAVS (Figure 5B).
Consistent with previous reports, NS3 protease from GBV-B also
inhibited human MAVS, while proteases from the more distantly
related pestivirus bovine viral diarrhea virus (BVDV) and flavivirus
yellow fever virus (YFV) did not antagonize MAVS (Figure 5) [43].
Thus, the property of antagonizing MAVS is shared and exclusive
to the group of viruses encompassing the HCV and GB viruses.
We next tested the effect of positively selected changes at
residue 506 on the ability of the GB viruses to inhibit MAVS.
Remarkably, changes at residue 506 away from ancestral valine
in MAVS allow it to signal in the presence of NS3 proteases from
all GB viruses (Figure 6, Figure S3). However, there are some
species- and virus-specific differences. For example, methionine
at residue 506 in Allen’s swamp monkey MAVS appears to
provide significant protection against protease from GBV-B virus
compared to other GB viruses and HCV (Figure 2A, Figure 6).
Also, alanine at residue 506 in red-mustached tamarin monkey
did not provide a much higher protection against antagonism by
GB viruses (compared to HCV, Figure 2A) than the ancestral
valine. These idiosyncratic differences likely reflect slightly
different properties of the HCV and GB virus proteases.
However, our overall data suggest that the ability of NS3
proteases to antagonize MAVS, and to be impeded by the same
adaptive changes in MAVS, is a phylogenetically discrete
characteristic exclusive to HCV and the three GBV viruses,
Figure 4. Protease-resistant MAVS better restricts HCV repli-
cation. Immunoblot showing HCV NS5A protein from lysates of Huh7-
K2040 cells transiently transfected with control plasmid (vector alone),
human, or rhesus MAVS variants with indicated mutations. The amount
of HCV restriction achieved by indicated MAVS variant is quantified
below the Western blot.
doi:10.1371/journal.pbio.1001282.g004
Figure 5. NS3 proteases from distantly related GB viruses inhibit human MAVS. (A) Phylogram made using NS3 sequence from the
indicated viruses. Bootstrap values are indicated for each branch. Scale represents 0.1 amino acid substitutions per site. Bovine viral diarrheal virus
(BVDV) and Yellow fever virus (YFV) are representative pesti- and flaviviruses, respectively. We refer to GBV-C and GBV-A viruses as hepaciviruses,
although they have not been formally assigned to a particular genus within the Flaviviridae family. GBV-C is also known as Hepatitis G virus (HGV).
CHV stands for canine hepacivirus [17]. Corresponding hosts that can be naturally infected by each virus are indicated on the right. (B) IFN-b
induction, as determined by luciferase firefly activity upon expression of human MAVS in the presence of NS3 protease from the corresponding virus
in (A). IFN-b induction is normalized as being 100% in absence of any protease. Experiments were performed in triplicate with error bars indicating
standard deviation.
doi:10.1371/journal.pbio.1001282.g005
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data demonstrate that non-human primates are susceptible to
infection by viruses that antagonize MAVS in a manner similar to
HCV.
To infer the minimum age of viruses that drove the evolution at
residue 506, we wanted to date these adaptive changes. We took
advantage of the phylogenetically well-characterized macaque
lineage, which includes rhesus macaque with the ‘‘resistant’’
change at position 506 [44]. We sequenced the C-terminus of
MAVS from six different Macaque species and found that all of
them, including the most ancestral species, the barbary macaque
M. sylvanus, possess the ‘‘resistant’’ glycine instead of the ancestral
valine at position 506 (Figure 7). Furthermore, we found no
polymorphisms at this position within 20 rhesus macaque samples,
suggesting that the change to glycine is likely a fixed change within
the species. Since the macaque lineage separated 5–8 million years
ago from that of baboons [44], which retain the ancestral valine at
position 506, our data suggest that the progenitor macaque lineage
encountered and adapted to a virus that antagonized MAVS at
least 5–8 million years ago.
Discussion
In this study, we have shown that positive selection in MAVS of
multiple primate species has independently resulted in its escape
from antagonism by hepaciviral proteases. Including baboons that
have acquired a change at residue 508, we found that 5 out of the
20 primates that we characterized possess MAVS resistant to
hepaciviral antagonism. Remarkably, MAVS resistance in four of
these species is a product of independently acquired changes at the
same single residue 506, which allow escape from hepaciviral NS3
protease recognition and cleavage.
MAVS as a Genetic Determinant of Hepaciviral Clearance
HCV cleaves MAVS in order to block the interferon response.
The importance of this strategy employed by HCV is highlighted
by the fact that interferon treatment is often clinically used to
successfully cure HCV infection. Furthermore, a polymorphism
near a type III interferon gene is associated with spontaneous and
treatment-induced clearance of HCV [45,46]. Thus, given the
importance of the interferon response, we hypothesize that
primates that possess MAVS resistant to cleavage by NS3 protease
should be better at clearing hepaciviral infections than species with
susceptible MAVS. Consistent with this idea, we found that
resistant variants of MAVS are better able to restrict HCV
replication in cell culture. Furthermore, although sampling of
hepaciviruses from primates has been sparse, thus far hepaci-
viruses have only been found in primates with ‘‘susceptible’’
MAVS, such as human, chimp, common marmoset, red-chested
mustached tamarin, and owl monkey [38]. In contrast, hepaci-
viruses were assayed for but not found in spider monkeys, which
have ‘‘resistant’’ MAVS [38]. Our study provides functional
evidence that implicates host genetics in determining the outcome
of diverse hepaciviral infections even between closely related
primate species.
Ancient Hepaciviruses as Drivers of MAVS Evolution
The remarkable case of convergent evolution at residue 506 is
indicative of adaptive evolution, likely driven by ancient viruses
(paleoviruses). Based on the phylogenetic and the functional
evidence using extant viruses as surrogates, we can attempt to infer
the nature of these paleoviruses, although our ‘‘indirect paleovir-
Figure 6. Protective effect of changes at residue 506 on
antagonism by GB virus proteases. IFN-b induction resulting from
expression of MAVS from indicated species, as determined by luciferase
firefly activity, is presented for either the ancestral ‘‘susceptible’’ valine
(light grey) or derived ‘‘resistant’’ variants (dark grey) at position 506 as
shown. Luciferase firefly activity is normalized as being 100% in absence
of the protease for each MAVS variant. Susceptibility to each of the GB-
virus protease is shown. x- and y-axes are the same for all graphs. All
experiments were performed in triplicate with error bars indicating
standard deviation.
doi:10.1371/journal.pbio.1001282.g006
Figure 7. Mapping the adaptive change at site 506 in the
Macaque lineage. Accepted Macaque phylogeny. Both species names
and common names are shown. Amino acid at position 506 in MAVS is
shown on the right. The escape variant glycine (G) is shown in red. Note
that the outgroup Olive baboon has valine (V) at position 506. This
indicates that the common ancestor of macaques underwent the
adaptive change 5–8 million years ago. MYA, million years ago.
doi:10.1371/journal.pbio.1001282.g007
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such paleoviruses. Functional evidence that changes at residue 506
provide protection from antagonism by HCV is consistent with the
hypothesis of ancient hepaciviruses being the causative agents of
the evolution at residue 506. Since HCV per se is a human-specific
virus, it is unlikely to have been responsible for MAVS evolution in
non-human primates. Instead, we sought to find viruses with
similar antagonistic properties as HCV. We found that NS3
proteases from GBV-A and GBV-C viruses, which naturally infect
non-human primates, not only share the ability to antagonize
MAVS but are also impeded by the same evolutionary changes at
residue 506 (GBV-B protease also behaves in a similar manner to
the other GB virus proteases and while it can experimentally infect
some New World primates, its natural host is not known). These
data suggest that despite the high degree of divergence, all
hepaciviruses are capable of antagonizing MAVS. This shared
property must have been present in their common ancestor and
subsequently inherited by all extinct and present-day hepaci-
viruses. Furthermore, this common ancestor must have been
present tens of millions of years ago. GBV-C viruses that infect
humans and chimps are thought to have co-diverged with their
ancestors 7 million years ago [47]. Similarly, GBV-A viruses are
thought to have co-speciated with their hosts over the course of last
20 million years [47,48]. Divergence of GBV-C from GBV-A and
from their common ancestor from HCV presumably occurred
even earlier. Taken together, these data suggest that hepaciviruses
capable of antagonizing MAVS are an extremely ancient group of
viruses that are old enough and distributed widely enough to be
responsible for driving MAVS evolution at residue 506. Consistent
with the ancient presence of hepaciviruses, we dated the change at
residue 506 in the macaque lineage to 5–8 million years ago. Our
findings imply that HCV and GB viruses represent the latest in a
continuum of hepaciviral infections that have plagued primates for
millions of years. Finally, it is interesting to note that MAVS in
three Old World monkeys (OWM) has independently evolved
resistance to hepaciviral antagonism despite the fact that
hepaciviruses have not yet been detected in OWM.
Multiple lines of evidence outlined above support the hypothesis
that ancient hepaciviruses were responsible for driving evolution in
MAVS. However, it is also formally possible that a different class
of viral antagonists unrelated to the hepaciviral NS3 proteases
drove the evolution at residue 506. Although it is not formally
possible to rule out such an alternative, there is little theoretical or
empirical evidence in support of this. Residue 506 is not an
‘‘Achilles’ heel’’ of MAVS that would make it an especially
attractive target for antagonism by other viruses. There does not
appear to be anything special about residue 506, except that it sits
within a stretch of residues that corresponds to the cleavage site for
hepaciviral protease NS3. Consistent with this idea, all other
known viral antagonists of MAVS, including proteases from other
viruses, interact with different regions of MAVS [9–12].
Furthermore, other residues under positive selection in MAVS
are spread throughout the length of the protein, suggesting that
MAVS can be antagonized along multiple surfaces and not just at
or near residue 506. Taken together, these reasons make it unlikely
that other viral antagonists besides hepaciviral proteases have
converged to drive the evolution at residue 506.
Inferring Paleovirology from Adaptive Evolution of MAVS
We have previously proposed that virus-driven adaptive
evolution of host antiviral factors can be used as a tool in
paleovirology, the study of ancient viruses and their impact of host
evolution [49,50]. The reasoning behind this idea is that positive
selection in host antiviral factors essentially represents viral
‘‘footprints’’ that can reveal the action of ancient viruses. An
inherent limitation of our ‘‘indirect’’ paleovirology approach is
that it cannot formally rule out the possibility that either an
unrelated virus or another selective pressure altogether was
responsible for the observed evolution. Thus, in the case of
evolution at residue 506 in MAVS, we cannot formally rule out
alternate selection scenarios. The discovery of endogenized
hepaciviral ‘‘fossils’’ in primate genomes might be an important
confirmation of ancient hepaciviruses and their ability to infect
primates. While such viral ‘‘fossils’’ would provide direct evidence
for existence of paleoviruses, they would not necessarily reveal the
functional consequences of these viruses on host evolution. Thus,
‘‘fossil’’-based and ‘‘indirect’’ paleovirology should be viewed as
complementary approaches, both of which are important to
determine the identity of paleoviruses and their impact on host
genomes.
One limitation of using adaptive evolution in host factors to
study paleovirology that has been previously discussed [50] is the
difficulty of deciphering the history of a single type of virus. For
example, protein kinase R (PKR) is a broad-spectrum antiviral
factor that is antagonized by a multitude of diverse viruses
including ssRNA and dsDNA viruses, and often at the same
domain. This is reflected in the large number of residues in PKR
that are evolving under positive selection [18]. Such overlapping
antagonism might obscure the history of individual viruses.
Moreover, every subsequent round of adaptation might overwrite
the paleoviral record of all previous infections. In contrast, despite
MAVS acting against a broad panel of RNA viruses, there are only
nine residues evolving under positive selection over primate
evolution. This suggests that only a few viruses directly antagonize
MAVS to drive its positive selection. This limited antagonism
makes it less likely that more than one virus will converge on the
same residue. Thus, studying proteins such as MAVS with sparse
positive selection widely distributed along its length offers the
opportunity to make paleoviral inferences with greater specificity.
Our study shows that the nature of the viral antagonist also
contributes to the specificity of the paleoviral record. For example,
it is surprising that the diverse hepaciviruses we tested have not
dramatically altered the substrate specificity of their NS3 proteases
over a long period of evolution. One explanation—supported by
recent data from genomic viral ‘‘fossils’’ [51]—is that long-term
virus evolution is much slower than expected due to functional
constraint [50]. Indeed, the NS3 proteases are highly constrained
because besides cleaving MAVS, they are also responsible for
cleaving the viral polypeptide at multiple locations. Thus, given
that paleovirology relies on the use of extant viruses as surrogates
of their ancient counterparts to test the function of positively
selected changes in host factors, viral ‘‘footprints’’ left by
functionally constrained antagonists like proteases are particularly
well suited for paleovirology [11,12].
Functional dissection of the interaction between residue 506 in
MAVS and HCV provides a model to study paleovirology using
extant viruses and host immune factors. This model can be applied
to the study of other residues in MAVS that have evolved under
positive selection in primates, which we suspect also reflect a
history of antagonism by other viruses. For example, coxsackie-
virus uses its 3C protease to cleave human MAVS between
residues 148 and 149 (Figure S4) [12]. Remarkably, residue 149
has evolved under one of the strongest signatures of positive
selection in MAVS (Figure 1B, Table S1). It is also interesting to
note that residue 423, which forms the P5 position within the
cleavage site for Hepatitis A virus protease, is also evolving under
positive selection (Figure 1B, Table S1, Figure S4). Future
experiments will be needed to establish the functional importance
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sites for all known protease antagonists of MAVS contain residues
evolving under positive selection suggests that the correlation is
unlikely to be simply a coincidence (Figure S4).
A particularly intriguing case of positive selection at residue 60
in MAVS also promises to reveal paleoviral insights (Figure 1B).
This residue has independently acquired changes in six primates.
In every instance, the ancestral asparagine has changed to serine
(Figure S5). This selective change likely reflects the pressure to
escape from some viral antagonism by evolving away from the
ancestral asparagine, while continuing to maintain MAVS
function, which might be particularly sensitive to changes at
residue 60. Residue 60 occurs within the highly conserved CARD
domain, which is utilized to directly interact with viral RNA
sensors RIG-I and MDA-5 [6]. Interestingly, MAVS in colobus
monkey is polymorphic for both asparagine and serine, suggesting
that the selective pressure driving the change might be very recent.
It will be interesting to functionally test whether serine at residue
60 provides protection from one of the known viral antagonists of
MAVS. Alternatively, the dramatic convergent evolution at
residue 60 might help discover a new viral antagonist of MAVS.
Materials and Methods
Sequencing MAVS cDNA
Isolation of total RNA was done as described previously [18].
Primate MAVS cDNAs were isolated by RT-PCR using 50 ng of
total RNA as template and TA-cloned into pCR2.1 (Invitrogen).
Primer MP-11, which sits upstream of the start site, and primer
MP-12, which is downstream of the stop codon, were used for RT-
PCR (Table S2). MP-34, along with MP-11 and MP-12, was used
for sequencing the cDNAs. MAVS cDNA sequences obtained in
this study are in the process of being submitted to GenBank.
Common marmoset sequence was obtained from the UCSC
Genome Browser.
Plasmid Construction
Primate MAVS cDNAs were prepared using 250 ng total
RNA as template and oligo dT primer (Superscript III,
Invitrogen). cDNAs were subsequently used as a template for
PCR (Phusion, NEB). MAVS cDNAs were cloned into pFLAG-
CMV-2 between HindIII and BglII downstream of and in frame
with FLAG tag.
Single amino acid changing point mutations were introduced in
human MAVS as follows: MP-51, a forward primer upstream of
the MAVS cDNA in pFLAG-CMV-2, was used in combination
with a reverse primer that included the desired change. A forward
primer with the desired change was then used with MP-52, a
reverse primer downstream of MAVS cDNA in pFLAG-CMV-2.
The resulting products from these two PCRs were used as a
template for stitch PCR with MP-51 and MP-52 primers. The
resulting PCR product, which included the desired change in
MAVS, was ligated into pFLAG-CMV-2 between HindIII and
BglII in frame with FLAG tag. The remaining single amino acid
changes in MAVS were introduced using similar stitching strategy,
but desired amino acid changes were achieved by stitching
together N- and C-terminal MAVS of different but closely related
species.
NS3/4A from GBV-B, GBV-C, HCV, and GBV-A was cloned
into pcDNA3.1/Hygro(2) between XbaI and HindIII down-
stream of and in frame with HA tag (cloned between NheI and
XbaI).
GBV-A NS3/4A was synthesized (Genscript Inc., Piscataway,
New Jersey) using strain A-lab sequence.
Other plasmids used in this study were: pJC453–IFN-b
promoter luciferase firefly reporter construct (kindly provided by
Zhijian Chen), pRL-TK–renilla transfection control construct
(Promega Inc.), pcDNA6-BVDVpro (kindly provided by Kui Li),
pcDNA6-YFVpro (kindly provided by Kui Li), Human MAVS
(C508Y) (previously described [52]), and pcDNA-Myc-sc-NS3
(S1165A) (previously described [33]).
Evolutionary Analyses
Amino acid sequence alignment was performed using ClustalW.
This amino acid alignment was used as input for DNA sequence
alignment in PAL2NAL. Aligned DNA sequences were subse-
quently used for all analyses done in PAML software. The well-
supported primate phylogeny (Figure 1A) [26] was used for
analyses done in PAML [28]. Maximum-likelihood analysis to
determine whether MAVS is evolving under positive selection and
to determine which residues are evolving under positive selection
was done using the sites models in codeml program of PAML [28].
Sites models allow the dN/dS ratio to vary among residues.
Branch models, which allow the dN/dS ratio to vary among
different branches of the phylogeny, were used to determine dN/
dS values for different lineages. Two-ratio tests to detect episodic
selection were performed by comparing a likelihood model that
allows dN/dS to vary across phylogeny to model with dN/dS fixed
at 1. REL and branch-site REL analysis were performed using a
web-based implementation of HyPhy package (www.datamonkey.
org). Branch-site REL is based on likelihood ratio tests that identify
all lineages with a proportion of sites that are evolving with dN/
dS.1, without making a priori assumptions about which lineages
these are in the phylogeny [29].
Luciferase Assays
5610
4 HEK293 cells were plated per well in 96-well plates and
transfected on the next day with LT1 (Mirus) transfection reagent.
The following plasmids were co-transfected in triplicates: MAVS
plasmid (2.5 ng), luciferase reporter construct pCJ453 (50 ng),
transfection control pRL-TK construct (10 ng), none or one of the
viral protease encoding plasmids (pJC1461—2.5 ng, pMP125—
2.5 ng, pMP122—10 ng, pMP123—2.5 ng, pMP126—10 ng),
and pFLAG-CMV-2 (enough to bring final DNA concentration
equal to 150 ng). One triplicate set of wells was transfected without
MAVS plasmid and one set without any DNA. 24 h after
transfection, Dual-Glo Luciferase Assay System (Promega) was
used to lyse the cells and measure luciferase firefly and renilla
activity with a luminometer. Amount of firefly or renilla activity in
wells transfected without any DNA was subtracted as background.
Firefly activity was divided by the renilla activity in the same well
to control for transfection efficiency. This firefly/renilla ratio from
cells expressing MAVS was divided by the firefly/renilla ratio from
wells without MAVS to calculate IFN-b fold induction, which was
then averaged across the set of three wells.
Immunoblot Analysis to Assay Cleavage
It was not possible to get enough lysate from a single well of a
96-well plate for immunoblot analysis. We therefore scaled the
entire transfection process by 4-fold in 24-well plates. Therefore,
20610
5 cells were plated per well in 96-well plates and transfected
with 4 times as much LT1 transfection reagent. Concentration of
all the plasmids was also increased 4-fold. 24 h after transfection,
cells were resuspended in 36 ml NTE buffer (10 mM Tris—pH 8,
1 mM EDTA, 50 mM NaCl) containing 0.18 mg protease
inhibitor cocktail Complete Mini (Roche). Cells were then lysed
on ice for 10 min in 44 ml of NP-40 buffer (1% NP-40, 0.2%
sodium-deoxycholate, 0.12 M NaCl, 20 mM Tris—pH 8) con-
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26 mol DTT,
and 1.2610
26 mol PMSF. Lysate was spun at maximum speed on
tabletop centrifuge for 10 min. 75 ml of supernatant was mixed
with 19 mlo f5 6 SDS sample buffer with 10% b-ME. Samples
were boiled for 10 min and then 5–10 ml was used for Western
blot analysis.
Mouse monoclonal anti-FLAG M2 antibody (Sigma-Aldrich)
was used to detect FLAG-tagged MAVS, and mouse monoclonal
anti-HA.11 antibody (Covance) was used to detect HA-tagged
HCV NS3/4A. Rabbit polyclonal anti-beta Actin antibody
(Abcam) was used to detect actin. HRP-linked anti-mouse and
anti-rabbit IgG antibodies (GE Healthcare) were used as
secondary anti-bodies. Primary anti-bodies were used at 1:1,000
dilution at 4u overnight and secondary anti-bodies were used at
1:10,000 dilution for 1 h at room temperature. SuperSignal West
Dura ECL substrate (Thermo Scientific) was used for detecting
HRP.
Co-Immunoprecipitation Assay
For co-immunoprecipitation analysis, HEK 293 cells were
transfected with empty vector or pcDNA-Myc-sc-NS3 (S1165A)
protease [33] that contains aa 21–32 of HCV NS4A fused to aa
1026–1206 of the HCV NS3 protease with the protease active site
mutation S1165A, as well as empty vector or MAVS-expressing
constructs. Cells were lysed in 1% Triton X-100, 150 mm NaCl,
and 25 mM Tris-Cl pH 7.5. Coimmunoprecipitation was per-
formed using FLAG M2-agarose beads (Sigma-Aldrich) followed
by immunoblot analysis using the following antibodies: anti-myc
(Abcam), anti-Flag M2-Peroxidase (Sigma-Aldrich), and anti-
tubulin (Sigma-Aldrich).
HCV Restriction Assay
Huh7-K2040 is a Huh7-based human hepatocyte cell line that
contains the self-replicating subgenomic replicon from HCV 1b
[34]. Huh7-K2040 is transfected with control vector or plasmid
expressing the indicated MAVS construct for 36 h. Cell lysates
were analyzed by immunoblot with antiserum specific to HCV
NS5A [53], tubulin (Sigma-Aldrich), and FLAG M2 (Sigma-
Aldrich) for detection of the various MAVS constructs. HCV
protein was further detected using the hyperimmune serum from
an HCV-infected patient that recognizes HCV proteins NS3,
NS4B, and NS5A [35]. Protein densitometry was determined
using the NIH ImageJ program. To derive fold restriction, NS5A
(rabbit polyclonal)/tubulin ratio for each sample was divided by
the NS5A(rabbit polyclonal)/tubulin ratio from the vector alone
control.
Supporting Information
Figure S1 Schematic of the RIG-I/MDA-5 pathway. Solid
arrows indicate direct interaction. Through a signaling cascade,
MAVS activates IRF-3 and NFk-B, which bind to and activate
IFN-b promoter.
(TIF)
Figure S2 Ability of MAVS from multiple primate species to
induce IFN-b activity. Same data as in Figure 2, but fold IFN-b
induction is not normalized. Induction of IFN-b promoter, as
measured by luciferase firefly activity, upon expression of MAVS
cDNA from corresponding species coexpressed with (+) or without
(2) HCV NS3/4A. Primates with MAVS capable of significant
IFN-b induction even in presence of HCV protease are
highlighted in bold. Human (C508R) refers to substitution of
Cysteine (C) at position 508 with Arginine (R) in human MAVS.
All experiments are done in triplicates, and error bars indicate
standard deviation.
(TIF)
Figure S3 Residue 506 provides protection against NS3/4A
from all hepaciviruses. Same data as in Figure 6 but includes data
from control groups (IFN-b induction in absence of any protease).
IFN-b induction due to expression of MAVS from indicated
species, as determined by luciferase firefly activity, is presented for
either the ancestral ‘‘susceptible’’ valine or derived ‘‘resistant’’
variants (in red) at position 506 as shown. Luciferase firefly activity
is normalized as being 100% in absence of the protease.
Susceptibility to each of the GB-virus protease is shown. y-axis is
the same for all graphs. All experiments done in triplicates. Error
bars indicate standard deviation.
(TIF)
Figure S4 Positive selection within the viral protease cleavage
sites. Cleavage sites in MAVS of three viral proteases have been
mapped so far (indicated by the scissors). Residues between which
proteases cleave MAVS are indicated. Note the presence of
residues under positive selection (triangles) within or proximal to
the cleavage sites of all three proteases.
(TIF)
Figure S5 MAVS protein alignment. Residues evolving under
positive selection are highlighted in yellow.
( )
Table S1 Statistical evidence for sites evolving under positive
selection in MAVS. Likelihood ratio tests for positive selection in
MAVS were done using NSsites model M7 versus M8 comparison
assuming F61 model of codon frequency in codeml program in
PAML software. Likelihood ratio tests were also performed using
random effects likelihood (REL), implemented in web-based
HyPhy package. Residues (highlighted in bold) with Bayes
Empirical Bayes (BEB) and REL calculated posterior probabilities
(PPr) equal to or greater than 0.9 for which dN/dS.1 are shown
in Figure 1B. NEB, Naive Empirical Bayes.
(TIF)
Table S2 List of primers used in the study. Primers are in 59 to
39 orientation.
(TIF)
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